[144] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals (AGIO) Form 144 notice: The filing reports a proposed sale of 200 common shares through Morgan Stanley Smith Barney on 08/27/2025 with an aggregate market value of $8,000. The shares were acquired the same day by stock option exercise and paid in cash.

The filing also discloses a prior sale by David Scadden of 1,400 common shares on 07/10/2025 for gross proceeds of $56,000. The issuer's outstanding shares are listed as 58,101,518, and the proposed sale is to be executed on the NASDAQ.

Positive

• Disclosure compliance: Form 144 filing demonstrates adherence to Rule 144 reporting requirements
• Clear acquisition details: Shares were acquired by stock option exercise and paid in cash, reducing ambiguity about the source

Negative

• Insider selling activity: Prior sale of 1,400 shares on 07/10/2025 and proposed sale of 200 shares may be noted by investors, though amounts are small

Insights

Securities Analyst

TL;DR: Small insider sale via option exercise: 200 shares ($8,000) scheduled on 08/27/2025; prior 1,400-share sale produced $56,000.

This Form 144 indicates routine insider liquidity rather than a material disposition. The 200-share proposed sale represents a negligible fraction of the 58,101,518 shares outstanding (0.00034%), suggesting minimal immediate market impact. The shares were acquired by stock option exercise and paid in cash, which is a common mechanism for insiders to monetize exercised options. The prior 1,400-share sale by David Scadden on 07/10/2025 is larger in absolute terms but remains immaterial relative to the outstanding share count.

Corporate Governance Expert

TL;DR: Filing shows compliance with Rule 144 for insider sales; transactions appear procedural, not indicative of governance issues.

The notice documents compliance with required disclosure for proposed insider sales and includes the required representations about material nonpublic information. The use of a brokerage firm and explicit listing of acquisition method (stock option exercise) and payment (cash) align with standard governance practices. There is no disclosure in the filing of any adverse information or unusual terms that would signal governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	200	8000.00	58101518	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/27/2025	Stock Option Exercise	Issuer			200	08/27/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DAVID SCADDEN 88 Sidney St. Cambridge MA 02139	Common	07/10/2025	1400	56000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AGIO Form 144 report?

The Form 144 reports a proposed sale of 200 common shares through Morgan Stanley on 08/27/2025 with an aggregate market value of $8,000.

How were the 200 AGIO shares acquired?

The 200 shares were acquired on 08/27/2025 by stock option exercise and paid for in cash.

Has the filer sold other AGIO shares recently?

Yes. The filing discloses a prior sale by David Scadden of 1,400 common shares on 07/10/2025 for gross proceeds of $56,000.

On which exchange will the proposed sale be executed?

The proposed sale is listed as to be executed on the NASDAQ.

How large is the proposed sale relative to outstanding shares?

The issuer has 58,101,518 shares outstanding; the proposed 200-share sale is a very small fraction of that total.